Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.
Pemphigus vulgaris (PV) is a rare, potentially fatal, autoimmune disease that affects the skin and mucous membranes. The PV antigen (PVA) has been characterized as desmoglein 3. PV patients carry HLA-DR4- or HLA-DR6-bearing extended haplotypes. We recently demonstrated that patients with active disease have high titers of PV autoantibodies of the IgG1 and IgG4 subclasses. Patients in remission, healthy unaffected relatives, and some MHC-matched normal individuals have low levels of PV autoantibodies, which are IgG1 only. Furthermore, intraperitoneal injection of IgG from patients with active disease caused clinical disease in mice, but IgG from patients in remission, healthy relatives, or MHC-matched normal individuals did not. We prepared 12 peptides of 30 amino acids each (peptides Bos 1-12) spanning the extracellular domain of PVA. Patients with active disease recognize peptides Bos 1 and Bos 6 with high titers of IgG1 and IgG4 autoantibodies. Patients in remission have IgG1 autoantibodies to peptide Bos 1 only, in statistically significantly lower titers (P < 0.01). They no longer have IgG4 subclass autoantibodies to peptide Bos 6. Healthy relatives and normal unrelated individuals have low levels of only IgG1 autoantibodies that recognize only Bos 1. In vitro studies indicate that Bos 6-specific IgG and, to a lesser extent, Bos 1-specific IgG can cause acantholysis. Our data suggest that Bos 6-specific IgG4 is probably the main acantholytic autoantibody, while Bos 1-specific IgG4 may act as a facilitator or enhancer of the process. In this study we illustrate some of the paradigms that demonstrate the interactions between the MHC, subclass of autoantibodies, and peptide specificities of the autoantibodies in the autoimmune process. Thus, PV provides an important model to study the pathogenesis of autoimmunity.
Bhol
K
K
Department of Dermatology, Boston University School of Medicine, MA 02118, USA.
Natarajan
K
K
Nagarwalla
N
N
Mohimen
A
A
Aoki
V
V
Ahmed
A R
AR
D000595:Amino Acid Sequence; D000818:Animals; D000831:Animals, Newborn; D000918:Antibody Specificity; D001323:Autoantibodies / Q000097:blood* / Q000145:classification / Q000633:toxicity*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology*; D001666:Binding Sites, Antibody; D001681:Biological Assay; D004797:Enzyme-Linked Immunosorbent Assay; D004947:Esophagus / Q000276:immunology / Q000473:pathology; D005190:Family; D005455:Fluorescent Antibody Technique; D015804:HLA-DR4 Antigen / Q000235:genetics; D015808:HLA-DR6 Antigen / Q000235:genetics; D000882:Haplorhini; D006239:Haplotypes; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000145:classification / Q000633:toxicity; D008285:Major Histocompatibility Complex; D051379:Mice; D008807:Mice, Inbred BALB C; D018448:Models, Immunological; D008969:Molecular Sequence Data; D010392:Pemphigus / Q000097:blood / Q000235:genetics / Q000276:immunology*; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry; D012016:Reference Values; D012867:Skin / Q000276:immunology* / Q000473:pathology
D001323:Autoantibodies; D015804:HLA-DR4 Antigen; D015808:HLA-DR6 Antigen; D007074:Immunoglobulin G; D010455:Peptides